TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06211959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification with Implementation Intentions
Description: Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
Study: NCT05573074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Photobiomodulator
Description: Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulator
Description: Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
Study: NCT06211959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification with Implementation Intentions
Description: Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Approach Bias Modification with Implementation Intentions
Description: Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
Study: NCT05750771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES
Description: Second-generation drug-eluting stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB
Description: Drug-coated balloon with paclitaxel as drug coating
Study: NCT06367257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: App Usage
Description: Conducting patient surveys with app

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: supportive care during and after radio(chemo)therapy according to hospial standards
Study: NCT05121974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem Pivoxil
Description: Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem Pivoxil
Description: Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Oral Azithromycin antibiotic (Macrolides)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxon
Description: IV Ceftriaxone (Cephalosporin)
Study: NCT06488131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA Pulpotomy
Description: Complete coronal MTA pulpotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment
Description: Conventional root canal treatment.
Study: NCT04845828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping
Description: Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3. Sentinel lymph node is excised

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine lymph node dissection
Description: 1. Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~2. Lymph node detection is performed.
Study: NCT05933239

Intervention type: DRUG
Group type: OTHER
Intervention: 68GaNOTA-Anti-MMR-VHH2
Description: Injection of the radiopharmaceutical and PET/CT imaging
Study: NCT04994002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-006
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-006
Description: Oral solution
Study: NCT05626998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
Study: NCT05689580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
Study: NCT05626998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
Study: NCT05689580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced diet
Description: Balanced diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced diet
Description: Balanced diet
Study: NCT05942235

Intervention type: OTHER
Intervention: Education
Description: Education
Study: NCT06520085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive mHealth application for patients undergoing RSA
Description: Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
Study: NCT04823104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visitation
Description: Home visitation for pregnancy follow-up
Study: NCT06520085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive mHealth application for patients undergoing RSA
Description: Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
Study: NCT05314608

Intervention type: COMBINATION_PRODUCT
Intervention: IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee
Description: Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
Study: NCT05288283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution
Study: NCT05988060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week.
Study: NCT06053515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rosie the Chatbot
Description: Participants in the intervention group will be using the chatbot to ask questions related to the mom and baby's health, provide feedback selecting thumbs up or thumbs down on the questions' response, and use the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus). In addition, participants will be taking a pre-test health survey, mid-test health survey, and post-test health survey.
Study: NCT05541809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Peppermint aroma inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water inhalation
Study: NCT06035900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocin
Description: single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
Study: NCT05936450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: delivery of placentrex gel after open flap debridement
Description: placentrex gel is placed after open flap debridement only in the test group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: Open Flap Debridement done in both test and control groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: Open Flap Debridement done in both test and control groups
Study: NCT06073496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator
Study: NCT04268485

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum KL-6 level
Description: Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
Study: NCT05299437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioiodine optimized therapy
Description: 124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status.
Study: NCT05967637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Whole body vibration
Description: The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
Study: NCT04772261

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 13C-Spirulina GEBT
Description: Various lots of 13C-Spirulina GEBT test meals

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 13C-Spirulina GEBT
Description: Various lots of 13C-Spirulina GEBT test meals
Study: NCT05075070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: two doses inactivated COVID-19 vaccine
Study: NCT06156982

Intervention type: DRUG
Intervention: Evusheld
Description: Administration of Evusheld 600 mg
Study: NCT05098795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: BA seeks to increase the positive reinforcement patients experience from their natural environment by promoting prosocial and valued experiences. BA has been found to improve substance use treatment retention and adherence, as well as medication adherence in low-income individuals with HIV/AIDS.
Study: NCT06342193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality group
Description: This group will use virtual reality glasses as distraction during cystoscopy.
Study: NCT05201664

Intervention type: PROCEDURE
Intervention: Surgical Extrusion
Description: Relocation of the remaining tooth structure to a more coronal position within the same original socket.
Study: NCT05547204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage
Description: Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage
Description: Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
Study: NCT04986956

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole coffee cherry extract
Description: 200mg WCCE

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison to WCCE
Study: NCT06342778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamine + Pyridoxine
Description: A single dose of R or T drug in each of 2 periods of the study after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxylamine + Pyridoxine
Description: A single dose of R or T drug in each of 2 periods of the study after meals
Study: NCT03872986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
Study: NCT06342778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclectin
Description: A single dose of R or T drug in each of 2 periods of the study after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclectin
Description: A single dose of R or T drug in each of 2 periods of the study after meals
Study: NCT03872986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer
Description: Beautifil II dental restorative material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Giomer
Description: Beautifil II dental restorative material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GIC
Description: Equia forte dental restorative material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GIC
Description: Equia forte dental restorative material
Study: NCT05770323

Intervention type: DIAGNOSTIC_TEST
Intervention: Uric acid level
Description: Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed

Intervention type: DIAGNOSTIC_TEST
Intervention: Uric acid level
Description: Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
Study: NCT06022523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Data acquisition using DT-400 pulse oximetry system
Description: Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
Study: NCT05306119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation method
Description: Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
Study: NCT05513209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid based multimodal anesthesia
Description: elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygopalatine ganglion block based multimodal anesthesia)
Description: elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
Study: NCT06042517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OGTT with unlabeled glucose and liver NMR
Description: Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OGTT with carbon-13 labeled glucose and liver NMR
Description: Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CGM glucose reading
Description: A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CGM glucose reading
Description: A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CGM glucose reading
Description: A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
Study: NCT06516523

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEMF and Control/Sham
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF and without PEMF
Description: Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
Study: NCT06042517

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CGM glucose reading
Description: A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
Study: NCT05543993

Intervention type: DRUG
Intervention: Bivalent COVID-19 Booster
Description: Bivalent COVID-19 Booster by Pfizer or Moderna

Intervention type: DRUG
Intervention: Bivalent COVID-19 Booster
Description: Bivalent COVID-19 Booster by Pfizer or Moderna
Study: NCT06444191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet(s) administered orally
Study: NCT06155396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.0 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240mg IV every 2 weeks
Study: NCT06252324

Intervention type: OTHER
Group type: OTHER
Intervention: Prime taper implant + cover screw
Description: tissue level implant placement with the addition of a cover screw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prime taper implant + healing screw
Description: bone level implant placement with the addition of a healing screw
Study: NCT05764447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined qigong Baduanjin and self-administered acupressure
Description: The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.